
April 7 (Reuters) - Savara Inc SVRA.O:
SAVARA ANNOUNCES ENCORE PRESENTATIONS FROM THE PHASE 3 IMPALA-2 TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT TWO UPCOMING SCIENTIFIC CONFERENCES